Brief: Vicore Amends Primary Endpoint To Accelerate Phase 3 Trial In Covid-19 Patients

Vicore Pharma Holding AB

03/06/2022 07:29

June 3 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * AMENDS PRIMARY ENDPOINT TO ACCELERATE THE PHASE 3 TRIAL IN
COVID-19 PATIENTS
    * BASED ON PROFILE OF C21 AND EMERGING COVID-19 DATA,
ONGOING
PHASE 3 TRIAL HAS BEEN AMENDED TO REVISE PRIMARY ENDPOINT AND
REDUCE SAMPLE SIZE
    * AMENDMENT HAS BEEN ADOPTED TO REFLECT CURRENT SARS-COV-2
VIRUS
LANDSCAPE AND WILL ACCELERATE STUDY COMPLETION
    * EXPECTED READ-OUT DURING Q3 2022
    * ATTRACT-3 TRIAL IS APPROACHING 300 PATIENTS ENROLLED AND
INCLUDES A LARGE INITIAL POPULATION OF UNVACCINATED PATIENTS
INFECTED BY DELTA VARIANT, JUSTIFYING CHANGE TO A MORTALITY
ENDPOINT AND TO COMPLETE TRIAL WITH THIS SAMPLE SIZE
    * TOP-LINE DATA WILL BE PRESENTED IN Q3 2022

Source text for Eikon:  ID:nWkrbMZrLh 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))